Pharmadule Morimatsu, a pharmaceutical/biopharmaceutical company, and WuXi Biologics, a global contract research development and manufacturing organization (CRDMO), entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.

The strategic cooperation starts with the integrated modular plant of two important production facilities in the Singapore CRDMO Center of WuXi Biologics, and will include design, manufacturing, FAT, installation, commissioning, and validation. The project will adopt a new generation of modular fabrication, and the majority of works will be built, assembled and FAT-tested in Morimatsu’s workshop. The quality, schedule, cost, and risk of the project will be well managed and controlled. Compared with conventional construction, this method also greatly shortens the project cycle.

Chris Chen, CEO of WuXi Biologics, said, “Singapore is one of the most advanced pharmaceutical hubs in the world, as well as a critical part of our global biomanufacturing network. By leveraging Pharmadule Morimatsu’s expertise and experience, we are confident that our Singapore CRDMO Center will contribute to our track record in establishing global sites successfully as demonstrated by our greenfield site in Ireland, further enabling global partners with premier quality services and solutions.”

Weihua Tang, CEO of Morimatsu LifeSciences, said, “WuXi Biologics is an important partner of our company, we are very delighted to cooperate with them once again. In this cooperation, Pharmadule Morimatsu will utilize a new generation of modular fabrication methods to assist WuXi Biologics in expanding production capacity, accelerating the empowerment of global pharmaceutical companies, reducing R&D costs, and benefiting patients worldwide.”